CIK 0001706431 · Large accelerated filer
Vir Biotechnology, Inc.
Sign in to watch- Ticker
- VIR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 812730369
- Phone
- 415-906-4324
- Business address
- 1800 OWENS STREET, SUITE 900, SAN FRANCISCO, CA, 94158
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $41,939
- in 1 filing, $42K under 10b5-1 plans
Net −$41,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 46 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-27 | Hatfield Jeffrey S. Director | Grant or award | +8,000 | 39,806 | ||
| 2026-05-27 | Hatfield Jeffrey S. Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2026-05-27 | Farid Ramy Director | Grant or award | +8,000 | 32,000 | ||
| 2026-05-27 | Farid Ramy Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2026-05-27 | BISCHOFBERGER NORBERT W Director | Grant or award | +8,000 | 21,333 | ||
| 2026-05-27 | BISCHOFBERGER NORBERT W Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2026-05-01 | SATO VICKI L Director | Sale 10b5-1 | −22,000 | $10.05 | $221K | 1,078,391 |
| 2026-04-29 | De Backer Marianne President and CEO | Other disposition | −233,532 | 714,613 | ||
| 2026-04-29 | De Backer Marianne President and CEO | Other acquisition | +233,532 | 286,650 | ||
| 2026-04-06 | De Backer Marianne President and CEO | Sale 10b5-1 | −72,559 | $9.16 | $664K | 948,145 |
| 2026-04-01 | SATO VICKI L Director | Sale 10b5-1 | −22,000 | $9.07 | $200K | 1,100,391 |
| 2026-03-23 | Sabatini Brent SVP, Chief Accounting Officer | Sale 10b5-1 | −7,711 | $9.12 | $70K | 61,902 |
| 2026-03-20 | O'Byrne Jason EVP & Chief Financial Officer | Other disposition | −2,500 | 160,115 | ||
| 2026-03-20 | O'Byrne Jason EVP & Chief Financial Officer | Other acquisition | +2,500 | 2,500 | ||
| 2026-03-02 | SATO VICKI L Director | Sale 10b5-1 | −21,800 | $9.50 | $207K | 1,122,591 |
| 2026-03-02 | SATO VICKI L Director | Sale 10b5-1 | −200 | $9.98 | $2K | 1,122,391 |
| 2026-02-25 | Eisner Mark EVP and Chief Medical Officer | Sale 10b5-1 | −1,889 | $9.82 | $19K | 154,024 |
| 2026-02-25 | de Verneuil Vanina EVP, General Counsel, Corp Sec | Sale 10b5-1 | −13,700 | $9.82 | $135K | 112,982 |
| 2026-02-24 | SATO VICKI L Director | Option exercise 10b5-1 | +42,377 | $1.49 | $63K | 1,186,768 |
| 2026-02-24 | SATO VICKI L Director | Sale 10b5-1 | −42,177 | $9.75 | $411K | 1,144,591 |
Page 2 of 54 · 1,063 trades